A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects

Phase 1CompletedNCT01513928

Pfizer12 enrolled

Overview

This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

Pf-04937319DRUG

Formulation A) Pf-04937319 50 mg - administered as tablet

Pf-04937319DRUG

Formulation B) Pf-04937319 50 mg - administered as capsule

Pf-04937319DRUG

Formulation C) Pf-04937319 50 mg - administered as capsule

Eligibility

Sex: ALLMin age: 21 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male and/or female subjects between the ages of 21 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG or clinical laboratory tests. * Subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 28-days after the last dose of treatment. * Body Mass Index (BMI) of 23 to 33 kg/m2 and a total body weight \>=50 kg (110 lbs). Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (excluding untreated seasonal allergies). * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug screen.

Locations (1)

Pfizer Investigational Site

Singapore, Singapore, Singapore